Use of spironolactone in dermatology

SKINmed

Volumn 8, Issue 6, 2010, Pages 328-332

  Rathnayake, Deepani ^a   Sinclair, Rodney ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; SPIRONOLACTONE;

ACNE VULGARIS; ALOPECIA; FEMALE; HIRSUTISM; HUMAN; OFF LABEL DRUG USE; PREGNANCY; REVIEW;

ACNE VULGARIS; ALDOSTERONE ANTAGONISTS; ALOPECIA; FEMALE; HIRSUTISM; HUMANS; OFF-LABEL USE; PREGNANCY; SPIRONOLACTONE;

EID: 79954431066     PISSN: 15409740     EISSN: 17517125     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Ober KP, Hennessy JF. Spironolactone therapy for hirsutism in a hyperandrogenetic woman. Ann Intern Med. 1978;89:643-644.
2. Gómez R, Núñez L, Caballero R, et al. Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1+minK channels. Br J Pharmacol. 2005;146:146-161.
3. Corvol P, Michaud A, Menard J, et al. Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology. 1975;97:52-58.
4. Dill-Muller D, Zaun H. Topical treatment of androgenetic alopecia with spironolactone. J Eur Acad Dermatol Venereol. 1997;9(suppl 1):S31.
5. Helfer EL, Miller JL, Rose LI. Side-effects of spironolactone therapy in the hirsute woman. J Clin Endocrinol Metab. 1988;66:208-211.
6. Yemisci A, Gorgulu A, Piskin S. Effects and side-effects of spironolactone therapy in women with acne. J Eur Acad Dermatol Venereol. 2005;19:163-166.
7. Danielson DA, Jick H, Hunter JR, Stergachis A, Madsen S. Nonestrogenic drugs and breast cancer. Am J Epidemiol. 1982;116:329-332.
8. Cunliffe WJ, Shuster S. Pathogenesis of acne. Lancet. 1969;i:685-687.
9. Odlind V, Chalstrom K, Michelson C, et al. Plasma androgenic activity in women with acne vulgaris in healthy girls before, during and after puberty. Clin Endocrinol (Oxf). 1982;16:243-249.
10. Lucky AW, McGuire J, Rosenfield RL, et al. Plasma androgens in women with acne vulgaris. J Invest Dermatol. 1983;81:70-40.
11. Schmidt JB, Spona J, Huber J. Androgen receptor in hirsutism and acne. Gynecol Obstet Invest. 1986;22:206-211.
12. Pierard GE. Follicle to follicle heterogeneity of sebum excretion. Dermatologica. 1986;173:61-65.
13. Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med. 1985;20:425-429.
14. Muhlemann MF, Carter GD, Cream JJ, et al. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol. 1986;115:227-232.
15. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000;43:498-502.
16. Shaw JC, White LE. Long-term safety of spironolactone in acne: results of an 8-year followup study. J Cutan Med Surg. 2002;6:541-545.
17. Randall V. Androgens: the main regulator of human hair growth. In: Camacho FM, Randall VA, Price VH, eds. Hair and Its Disorders: Biology, Pathology and Managements. London, England: Martin Dunitz Ltd; 2000:69-82.
18. Farquhar C, Lee O, Toomath R, Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev. 2001;(4):CD000194.
19. Ferriman DM, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol. 1961;21:1440-1447.
20. Cumming DC, Yang JC, Rebar RW, Yen SS. Treatment of hirsutism with spironolactone. JAMA. 1982;247:1295-1298.
21. Spritzer PM, Lisboa KO, Mattiello S, et al. Spirolactone as a single agent for long term therapy of hirsute patients. Clin Endocrinol (Oxf). 2000;52:587-594.
22. Gökmen O, Senöz S, Gülekli B, et al. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. Gynecol Endocrinol. 1996;10:249-255.
23. Kelestimur F, Sahin Y. Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertil Steril. 1998;69:66-69.
24. Lumachi F, Rondinone R. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertil Steril. 2003;79:942-946.
25. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97:247-254.
26. Norwood OT. Male pattern baldness. Classification and incidence. South Med J. 1975;68:1359-1370.
27. Olsen EA. Female pattern hair loss. J Am Acad Dermatol. 2001;45:S70-S80.
28. Sinclair RD, Dawber RP. Androgenetic alopecia in men and women. Clin Dermatol. 2001;19:167-178.
29. Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005;10:184-189.
30. Van der Donk J, Passschier J, Knegt-Junk C, et al. Psychological characteristics of women with androgenetic alopecia: a controlled study. Br J Dermatol. 1991;125:248-252.
31. Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. J Eur Acad Dermatol Venereol. 2001;15:137-139.
32. Arias-Santiago S, Gutiérrez-Salmerón MT, Buendía-Eisman A, Girón-Prieto MS, Naranjo-Sintes R. Hypertension and aldosterone levels in women with early-onset androgenetic alopecia. Br J Dermatol. 2010;162:786-789.
33. Whiting DA. Scalp biopsy as a diagnostic and prognostic tool in androgenetic alopecia. Dermatol Ther. 1998;8:24-33.
34. Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol. 2001;116:452-455.
35. Hillmer AM, Hanneken S, Ritzmann S, et al. Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet. 2005;77:140-148.
36. Levy-Nissenbaum E, Bar-Natan M, Frydman M, et al. Confirmation of the association between male pattern baldness and the androgen receptor gene. Eur J Dermatol. 2005;15:339-340.
37. Yip L, Zaloumis S, Irwin D, et al. Gene-wide association study of the aromatase gene (CYP19A1) with female pattern hair loss. Br J Dermatol. 2009;161:289-294.
38. Sawaya ME, Price VH. Different levels of 5 alpha reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997;109:296-300.
39. Schmidt JB, Lindmaier A, Trenz A, et al. Hormone studies in females with androgenetic hair loss. Gynecol Obstet Invest. 1991;31:235-239.
40. Messenger AG, Sinclair R. Follicular miniaturization in female pattern hair loss: clinicopathological correlations. Br J Dermatol. 2006;155:926-930.
41. Olsen EA. The midline part: an important physical clue to the clinical diagnosis of androgenetic alopecia in women. J Am Acad Dermatol. 1999;40:106-109.
42. Sinclair R, Jolley D, Mallari R, Magee J. The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telegen hair loss in women. J Am Acad Dermatol. 2004;51:189-199.
43. De Lacharriere O, Deloche C, Misciali C, et al. Hair diameter diversity: a clinical sign reflecting the follicle miniaturization. Arch Dermatol. 2001;137:641-646.
44. Rushton DH, Ramsay ID, Norris MJ, et al. Natural progression of male pattern baldness in young men. Clin Exp Dermatol. 1991;16:188-192.
45. Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43:768-776.
46. Trüeb RM; Swiss Trichology Study Group. Treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology. 2004;209:202-207.
47. Shapiro J. Hair loss in women. N Engl J Med. 2007;357:1620-1630.
48. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152:466-473.
49. Rushton DH, Futterweit W, Kingsley D, et al. Quantitative assessment of spironolactone treatment in women with diffuse androgen dependent alopecia. J Soc Cosmet Chem. 1991;42:317-325.
50. Yazdabadi A, Green J, Sinclair R. Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl. Australas J Dermatol. 2009;50:113-114.
51. Hoedemaker C, van Egmond S, Sinclair R. Treatment of female pattern hair loss with a combination of spironolactone and minoxdil. Australas J Dermatol. 2007;48:43-45.